FDA panel urges rejection of experimental Alzheimer’s drug

WASHINGTON (AP) — Government health advisers have sharply criticized an experimental Alzheimer’s drug. The panel on Friday urged the Food and Drug Administration to reject the treatment. They noted a number of flaws with study data submitted by drugmaker Biogen, which is developing the drug along with a Japanese company. The FDA is not required to follow the group’s advice, though it often does. The drug likely would be very expensive and could have a profound impact on health